CASI PharmaceuticalsFRA:ENM 29 Piotroski F-Score is 4 as of Jul. 06, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review. Among 1,332 Biotechnology companies, CASI Pharmaceuticals ranks better than 74.1% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
CASI Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for CASI Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
FRA:ENM'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 5
Current: 4
During the past 13 years, the highest Piotroski F-Score of CASI Pharmaceuticals was 5. The lowest was 2. And the median was 4.
CASI Pharmaceuticals (FRA:ENM) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
CASI Pharmaceuticals Piotroski F-Score Related Terms
CASI Pharmaceuticals Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ENM vs ITRMF, OGEN, AZTR: Piotroski F-Score Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
CASI Pharmaceuticals's current Net Income (TTM) was -41.95.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
CASI Pharmaceuticals's return on assets of this year was -0.81841238. CASI Pharmaceuticals's return on assets of last year was -0.52915779.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
CASI Pharmaceuticals's gearing of this year was 0.0387553. CASI Pharmaceuticals's gearing of last year was 0.04344955.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
CASI Pharmaceuticals's current ratio of this year was 0.27092272. CASI Pharmaceuticals's current ratio of last year was 1.08568884.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
CASI Pharmaceuticals's number of shares in issue this year was 27.098. CASI Pharmaceuticals's number of shares in issue last year was 19.152.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
CASI Pharmaceuticals's gross margin of this year was 0.48888889. CASI Pharmaceuticals's gross margin of last year was 0.38747745.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
CASI Pharmaceuticals's asset turnover of this year was 0.35466942. CASI Pharmaceuticals's asset turnover of last year was 0.38550586.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
1
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
CASI Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
CASI Pharmaceuticals (FRA:ENM) has a Piotroski F-Score of 4 as of Jul. 06, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CASI Pharmaceuticals and its competitors. This is near median its historical median of 4.00. Over the past decade, CASI Pharmaceuticals' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, CASI Pharmaceuticals ranks #345 out of 1332 companies in the Biotechnology industry, placing it in the top 25.9%.
Is CASI Pharmaceuticals' Piotroski F-Score too high?
CASI Pharmaceuticals' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. CASI Pharmaceuticals' value of 4 is 33.3% above this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #345 out of 1332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Piotroski F-Score compare to ITRMF and OGEN?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #345 out of 1332 companies for Piotroski F-Score. This puts CASI Pharmaceuticals in the upper half of its industry. The industry median Piotroski F-Score is 3.00. CASI Pharmaceuticals' value of 4 is 33.3% above this benchmark. Historically, CASI Pharmaceuticals' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, CASI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Piotroski F-Score of 4. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Piotroski F-Score is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:ENM:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
Industry Position: 33.3% above the Biotechnology median (#345 of 1332)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
